Pre-prints
Pre-prints of the Dalton Discussion papers are provided to participants of the meeting in order that questions to the authors and further comments may be prepared in advance of the meeting. Most of the time at the meeting will be devoted to a discussion that will be conducted on the assumption that the papers have already been read.
Authors should note that these pre-prints are not proofs. Proofs of each paper will be sent to the authors immediately after the meeting itself.
Please note that the quality of the pdf and pre-print is lower than that of the final published volume. The pre-prints are on A4 size paper.
To see the Scientific Programme with paper titles please download the pdf programme.
The following speakers will present their work at DD10:
Keynote Lecture
Radiometallodrugs in diagnosis and targeted therapy
Helmut Mãcke, University Hospital Basel, Switzerland
Downloadable Files
10/K1. Some uses of transition metal complexes as anti-cancer and anti-HIV agents Raymond Wai-Yin Sun, Dik-Lung Ma, Ella Lai-Ming Wong and Chi-Ming Che*, University of Hong Kong, Hong Kong 
PDF
10/D1. Pre-association of polynuclear platinum agents on a protein, human serum albumin. Implications for drug design Eva I Montero, Brad T Benedetti, John B Mangrum, Michael J Oehlsen, Yun Qu and Nicholas P Farrell*, Virginia Commonwealth University, USA PDF
10/D2. Gold(I) chloride adducts of 1,3-bis(di-2-pyridylphosphino)propane: synthesis, structural studies and antitumour activity Anthony S humphreys, Aleksandra Filipovska, Susan J Berners-Price*, George A Koutantonis, Brian W Skelton and Allan H White, University of Western Australia, Australia PDF
10/D3. Iron-binding properties of plant phenolics and cranberry's bio-effects Maolin Guo*, Carlos Perez, Yibin Wei, Elise Rapoza, Gregory Su and Fadi Bou-Abdallah, University of Massachusetts, USA PDF
10/D4. New CO-releasing molecules based on cyclopentadienyliron carbonyls David Scapens, Harry Adams, Tony R Johnson, Brian E Mann*, Philip Sawle, Rehan Aqil, Trevor Perrior and Roberto Motterlini, University of Sheffield, UK PDF
10/D5. Cu-ASTM: A radiopharmaceutical for the PET imaging of hypoxia Amy L V
vere and Jason S Lewis*, Washington University in St Louis, USA PDF
10/D6. 106Ru radiolabelling of the antitumour complex [
6-(fluorine)Ru(en)Cl]PF6 James D Hoeschele, Abraha Habtemariam, Jeanette Muir and Peter J Sadler*, Michigan State University, USA PDF
10/D7. Synthesis and characterization of a Gd(III) based contrast agent responsive to thiol containing compounds Carla Carrera, Giuseppe Digilio, Simona Baroni, Daniela Burgio, Simona Consol, Franco Fedeli, Dario Longo, Armando Mortillaro and Silvio Aime*, Universita di Torino, Italy PDF
10/D8. Designing Zn(II) and Cu(II) derivatices as probes for in vitro fluorescence imaging Sofia I Pascu*, Philip A Waghorn, Timothy D Conry, Helen M Betts, Jonathan R Dilworth, Grant C Churchill, Tzveta Pokrovska, Martin Christlieb, Franklin I Aigbirhio and John E Warren, University of Oxford, UK PDF
10/D9. How do HYNIC-conjugated peptides bind technetium? Insights from LC-MS and stability studies Robert C King, M Bashir-Uddin Surfraz, Stefano C G Biagini, Philip J Blower* and Stephen J Mather, King's College London, UK PDF
10/K3. Metal based drugs: from serendipity to design Simon Paul Fricker*, AnorMED Inc., Canada PDF
10/D10. Probing key coordination interactions: configurationally restricted metal activated CXCR4 antagonists Graeme McRobbie, Gina C Valks, Christopher J Empson, Abid Khan, Jon D Silversides, Christophe Pannecouque, Erik De Clercq, Steven G Fiddy, Adam J Bridgeman, Nigel A Young and Stephen J Archibald*University of Hull, UK PDF
10/D11. Lanthanide containing compounds for therapeutic care in bone resorption disorders Cheri A Barta, Kristina Sachs-Barrable, Jessica Jia, Katherine H Thompson, Kishor M Wasan and Chris Orvig*, University of British Columbia, Canada PDF
10/D12. Modifications of boronic ester pro-chelators triggered by hydrogen peroxide tune reactivity to inhibit metal-promoted oxidative stress Louise K Charkoudian, David M Pham, Ashley M Kwon, Abbey D Vangeloff and Katherine J Franz*, Duke University, USA PDF
10/K4. Targeted 
-therapy: past, present, future?
Martin W Brechbiel*, National Institute of Health, USA PDF
10/D13. The exocyclic functionalisation of bis(thiosemicarbazonate) complexes of zinc and copper: the synthesis of monomeric and dimeric species Martin Christlieb, Harriet S R Struthers, Paul D Bonnitcha, Andrew R Cowley and Jonathan R Dilworth*, University of Oxford, UK PDF
10/K5. Developing new metal-based therapeutics: challenges and opportunities Trevor W Hambley*, University of Sydney, Australia PDF
10/D14. Novel platinum(II)-based anticancer complexes and molecular hosts as their drug delivery vehicles Nial J Wheate, Robin I Taleb, Anwen M Krause-Heuer, Rebekah L Cook, Shaoyu Wang, Vincent J Higgins and Janice R Aldrich-Wright*, University of Western Sydney, Australia PDF
10/D15. Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy Claudine Scolaro, Adrian B Chaplin, Christian G Hartinger, Alberta Bergamo, Moreno Cocchietto, Bernhard K Keppler, Gianni Sava and Paul J Dyson*, Ecole Polytechnique Fédérale de Lausanne, Switzerland PDF
10/D16. The influence of phenolic hydroxy substitution on the electron transfer and anti-cancer properties of compounds based on the 2-ferrocenyl-1-phenyl-but-1-ene motif Elizabeth Anne Hillard, Pascal Pigeon, Anne Vessières, Christian Amatore and Gérard Jaouen*, Ecole Nationale Supérieure de Chimie de Paris, France PDF
10/D17. Functionalised cyclopentadienyl titanium compounds as potential anticancer drugs Olivia R Allen, Andrew L Gott, John A Hartley, Janet M Hartley, Richard J Knox and Patrick C McGowan*, University of Leeds, UK PDF
PDF files require 
Adobe Acrobat Reader
